Evidence map›Paper›PMID 40051245›Full record

ArticleSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association2025

Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia.

Bandar Al-Judaibi, Hazzaa Alzahrani, Ali Alahmari, Fahad Almohareb, Ali Albenmousa, Waleed Al-Hamoudi, Saad Alghamdi, Ibrahim Alrajhi, Shaykhah Alotaibi, Nour AlMozain and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Sickle cell hepatopathy in Oman: An emerging burden demanding regional action.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bandar Al-JudaibiDepartment of Liver and Health Small Bowel Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Hazzaa AlzahraniHematology Department, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ali AlahmariHematology Department, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Fahad AlmoharebHematology Department, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ali AlbenmousaDepartment of Liver and Health Small Bowel Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Waleed Al-HamoudiDepartment of Liver and Health Small Bowel Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Saad AlghamdiDepartment of Liver and Health Small Bowel Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ibrahim AlrajhiDepartment of Liver and Health Small Bowel Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Shaykhah AlotaibiHematology Department, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Nour AlMozainPathology and Laboratory Medicine, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Fuat SanerOrgran Transplant Centre of Excellence, Adult Transplant Intensive Care Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Christophe DuvouxDepartment of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Creteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThere is an increasing recognition of the need for a specialized hepatohematology program in countries with a high prevalence of sickle cell disease. This program would be tailored specifically for patients with sickle cell disease, addressing the unique challenges they face, including the management of liver and biliary complications, and hematological issues associated with their condition. By integrating hepatology and hematology expertise, we can improve knowledge of liver SCD-related diseases, and patient outcomes, enhance care coordination, and provide comprehensive management strategies for this vulnerable population. While the primary focus of this program is on SCD-related liver disease, there may be opportunities shortly to expand its scope to include patients with various hematological liver diseases.

Indexed as

Anemia, Sickle CellGastroenterologyHematologyLiver DiseasesHumansSaudi Arabia

Identifiers

PMID40051245
PMCPMC11978243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.